Pancreatic Cancer section

Prostate Cancer News & Features

Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life

Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life

The impact of prostate cancer treatment is well documented; however, in this study, researchers sought to determine the effect on health-related quality of life for patients from diagnosis through treatment planning to initiation of treatment.

Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk

Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk

An analysis of an intervention arm of the PLCO Cancer Screening Trial evaluated the risk of prostate cancer relative to dietary consumption of isoflavones, a dietary compound found in some plant foods.

Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret

Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret

A survey followed up with an assessment via validated tools determined that patients with prostate cancer who experienced regret after radical prostatectomy were more susceptible to depression-associated sleep disorders.

Androgen Deprivation Therapy for Prostate Cancer Increases Risk of CVD

Androgen Deprivation Therapy for Prostate Cancer Increases Risk of CVD

The risk of cardiovascular disease such as heart failure, arrhythmias, and conduction disorders are greater in men with localized prostate cancer who were treated with androgen deprivation therapy.

Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer

Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer

Osteoporosis medications were found to reduce bone mineral density loss and risk of fracture in men with nonmetastatic prostate cancer being treated with androgen-deprivation therapy.

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.

Cabazitaxel Does Not Prolong Overall Survival vs Docetaxel in Metastatic Prostate Cancer

Cabazitaxel Does Not Prolong Overall Survival vs Docetaxel in Metastatic Prostate Cancer

Cabazitaxel does not prolong OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer compared with the first-line chemotherapy agent docetaxel.

Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms

Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms

Meta-analysis of data from more than 50 studies reaffirms that vasectomy is not associated with increased risk of prostate cancer.

Obese Men at Higher Risk for Aggressive Prostate Cancer

Obese Men at Higher Risk for Aggressive Prostate Cancer

Study found taller and heavier males were more likely to develop prostate cancer, and they are also more likely to die of the disease.

Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years

Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years

Study results show that patients with prostate cancer express treatment decision regret, with concerns regarding sexual function, bowel function, and PSA most commonly associated with regret.

Prostate Cancer Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs